| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10895632 | Biochimica et Biophysica Acta (BBA) - Reviews on Cancer | 2011 | 7 Pages |
Abstract
Cyclin-dependent kinase inhibitor 1C CDKN1C (p57KIP2) regulates several hallmarks of cancer, including apoptosis, cell invasion and metastasis, tumor differentiation and angiogenesis. p57KIP2 is generally not mutated in cancer, but its expression is downregulated through epigenetic changes such as DNA methylation and repressive histone marks at the promoter. This opens up possibilities for therapeutic intervention through reactivation of p57KIP2 gene expression. Furthermore, p57KIP2 has been tested as a prognostic factor for many types of cancer, even differentiating between early and late stage cancer. In this review, the multifunctional tumor suppressor capabilities of p57KIP2, the mechanisms of p57KIP2 transcriptional repression in cancer, and the therapeutic potential of reactivation of p57KIP2 protein expression will be discussed.
Keywords
IGF2Epigallocatechin-3-gallateCMLCpGMASH1bHLHCIP/KIPcdkn1cBcl-xLSCFPACAPSAHAS-phase kinase-associated protein 2EZH2MyoDBWSBCR-ABLSkp2Limk1Bcl-2CDK interacting protein/Kinase inhibitory proteinCDKAMLLIM domain kinase 1JnkPAPAHDACEGCGc-Jun N-terminal kinaseDNAp57Kip2basic helix–loop–helixdeoxyribonucleic acidSuberoylanilide hydroxamic acidmicro-ribonucleic acidUltravioletenhancer of zeste homolog 2Myogenic differentiationCancerTumor suppressorES cellsEmbryonic stem cellsBeckwith–Wiedemann syndromeCytosine-phosphate-GuanineVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)B-cell lymphoma 2Diffuse large B cell lymphomaacute myeloid leukemiahairy and enhancer of split 1MiRNAHes1histone deacetylaseRho-associated protein kinasepituitary adenylate cyclase activating polypeptidecyclin-dependent kinaseRock
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Edel Kavanagh, Bertrand Joseph,